Core Viewpoint - The company, 来凯医药-B (02105.HK), has announced a placement agreement to issue 36 million shares at a price of HKD 16.30 per share, which represents approximately 8.8% of the current issued share capital and about 8.1% of the enlarged issued share capital after the placement [1] Summary by Relevant Sections - Placement Details - The company will issue a total of 36 million shares through an exclusive placement agent [1] - The placement price is set at HKD 16.30 per share [1] - Financial Implications - The estimated gross proceeds from the placement will be approximately HKD 586.8 million, with net proceeds expected to be around HKD 577.5 million [1] - Use of Proceeds - Approximately 90% of the net proceeds will be allocated for research and development of clinical and pre-clinical pipeline projects [1] - The remaining 10% will be used for general and corporate purposes [1]
来凯医药-B(02105.HK)拟配售合共3600万股 总筹5.87亿港元加码研发投入